RTK-driven feedback reactivation of AKT or ERK signaling has been identified as a key driver of drug resistance in cancers treated with AKT and mTOR inhibitors or BRAF and MEK inhibitors (Corcoran et al., 2012; Turke et al., 2012; Sun and Bernards, 2014; Datta et al., 2017; Fedele et al., 2018; Wong et al., 2018; Ahmed et al., 2019; Lu et al., 2019; Leung et al., 2020). Here, MTOR is linked to cancer.